Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04208)(COMPLETED)

• Subject ratings for individual product attributes [ Time Frame: On the study day, after dose of each product ] [ Designated as safety issue: No ]
• Subject rating for likely compliance with daily dosing, [ Time Frame: On the study day, after dose of each product ] [ Designated as safety issue: No ]
• Subject preference for glass or plastic bottle [ Time Frame: On the study day, after dose of each product ] [ Designated as safety issue: No ]
• Subject response to if they would want a prescription for their preferred product and if they would recommend the product [ Time Frame: On the study day, after dose of each product ] [ Designated as safety issue: No ]
• Subject response to whether they preferred inhaled corticosteroid with or without aftertaste, and/or scent/odor, [ Time Frame: On the study day, after dose of each product ] [ Designated as safety issue: No ]

This was a one-day single dose trial conducted to compare patient's preference for Nasonex® (mometasone) versus Flonase® nasal spray. Each patient was randomized to take one dose (2 sprays in each nostril) of Nasonex or Flonase. Thirty minutes later, each patient was to take one dose of the opposite medication. Questionnaires were given to each patient after each drug dose to evaluate patient product preference.

• Drug: Mometasone Furoate Nasal Spray
  One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
  Other Name: Nasonex, SCH 032088
• Drug: fluticasone nasal spray
  One dose (2 sprays in each nostril) of fluticasone nasal spray
  Other Name: Flonase®

• Active Comparator: Nasonex Followed by Flonase
  Interventions:

  • Drug: Mometasone Furoate Nasal Spray
  • Drug: fluticasone nasal spray
• Active Comparator: Flonase Followed by Nasonex
  Interventions:

  • Drug: Mometasone Furoate Nasal Spray
  • Drug: fluticasone nasal spray

Inclusion Criteria:

• Subject must have been 18-65 years of age, of either sex and any race.
• Subject must have had symptomatic allergic rhinitis with a total nasal symptom (congestion, rhinorrhea, sneezing, itching) severity score of <6 but >2; congestion must have been <2.
• Subject must have been free of any clinically significant disease (other than allergic rhinitis) that would interfere with study evaluations.
• Subject must have understood and been able to adhere to the dosing and visit schedule.

Exclusion Criteria:

• Subject had used any investigational product within 30 days prior to enrollment.
• Subject was in a situation or condition that, in the opinion of the investigator, may have interfered with optimal participation in the study.
• Subject was participating in any other clinical study(ies).
• Subject was using any nasal lavage fluid or spray.
• Subject was using any perfume during the study day.
• Subject was using any oral rinse during the study day.
• Subject had used topical or oral nasal decongestants in the past 1 week.
• Subject had used a nasal corticosteroid in the previous 2 weeks.
• Subject had anosmia or ageusia (absence of the sense of smell or taste).
• Subject had been using medications which are associated with anosmia or ageusia in the 2 weeks prior to testing.
• Subject had a respiratory infection in the 2 weeks prior to testing.